Aurenar raises $5.7 million in an oversubscribed seed round co-led by the Go Red for Women Venture Fund and Solas BioVentures. The company plans to use the capital for final device engineering, verification and validation testing, and FDA regulatory submissions for its V-Link transauricular vagus nerve stimulation platform.
Aurenar raises $5.7 million in seed funding to scale its non-invasive V-Link transauricular vagus nerve stimulation platform for intensive care patients. The Go Red for Women Venture Fund and Solas BioVentures co-lead the round.
Washington University in St. Louis startup Aurenar receives FDA Breakthrough Device designation for an earbud-like device designed to improve stroke outcomes after a ruptured brain aneurysm. Its approach uses non-invasive neuromodulation.
Jul 2026 · Washington University School of MedicineNews article
Aurenar receives FDA Breakthrough Device designation for its non-invasive neuromodulation therapy designed to reduce cerebral vasospasm following brain hemorrhage. The designation marks a regulatory milestone for its V-Link platform.
